Supplementary Table. Sensitivity Analysis of Estimated Nirsevimab Effectiveness Against Medically Attended Acute Respiratory Illness and Hospitalization From Respiratory Syncytial Virus, Overall and by Child’s Respiratory Syncytial Virus Season — Yukon-Kuskokwim Region, Alaska, October 23, 2023–June 30, 2024

Details

• Alternative Title:
  Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children — Yukon-Kuskokwim Delta Region, Alaska, October 2023–June 2024: Supplementary Table. Sensitivity Analysis of Estimated Nirsevimab Effectiveness Against Medically Attended Acute Respiratory Illness and Hospitalization From Respiratory Syncytial Virus, Overall and by Child’s Respiratory Syncytial Virus Season — Yukon-Kuskokwim Region, Alaska, October 23, 2023–June 30, 2024
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.).
• Description:
  Supplementary Table. Morbidity and Mortality Weekly Report, Vol. 73, No. 45, November 14, 2024
• Subjects:
  Disease Control Disease Notification Public Health Public Health Surveillance Respiratory Syncytial Virus Infections / Prevention & Control
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2024; v. 73, no. 45
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Genre:
  Tables ; Statistics
• Place as Subject:
  United States
• Pages in Document:
  1 pdf page
• Volume:
  73
• Issue:
  45
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:ef708dc742aa1e8cb981c845a81b9b701e4b74af9b9ff9b57d5b260b5763e4b949b49da4ecb88f950b0500b9f05ebc4d27cf7b3db75c2b804d7e9f8e88553485
• Download URL:
  https://stacks.cdc.gov/view/cdc/168888/cdc_168888_DS1.pdf
• File Type:
  [PDF - 140.11 KB ]